Share

Sheva Sanders to Present at FCPA & Anti-Corruption in Life Sciences Forum

Speaking Engagement
06.28.2017

Stinson Leonard Street partner Sheva Sanders will present at the American Conference Institute's 11th Annual Advanced Forum on FCPA & Anti-Corruption in the Life Sciences Industry June 26-28, 2017 at the Park Lane Hotel in New York City.

The half-billion dollar FCPA settlement with a pharmaceutical giant multinational at the end of 2016 testifies to U.S. authorities’ continued focus on the life sciences industry in its pursuit of global anti-corruption violations. At the same time, the new U.S. administration has increased anxiety amongst anti-bribery and compliance experts regarding the nature of such enforcement. ACI’s Advanced Life Sciences Forum is as timely and pertinent as ever, and the industry’s anti-corruption practitioners ought to remain alert in the coming months.

Sheva will present at 11:45 a.m. June 28 as part of the "Compliance LAB Teetering on the Edge of Legality and Ethics: How to Minimize the Most Common Risks with Physician-Owned Distributors" panel. The talk will cover:

  • A contemporary assessment of PODs as they are addressed by the Sunshine Act, Stark Law and Anti-Kickback Statute
  • How doctors and corporations are discovering novel ways to “cut corners” and “hook” clients to products in which they have a financial stake
  • Special focus on implant procedures and how entities (physicians, medical device manufacturers, health care providers, hospitals, etc.) expose themselves to the risk of violating anti-corruption compliance


The forum is the go-to event for professionals responsible for FCPA/anti-corruption compliance in a pharmaceutical, biotechnology, medical device and clinical research companies.

For more information on the forum, or to register, visit ACI's website.

Sheva is a partner in the firm's Minneapolis office. She advises health care, managed care, medical device, pharmaceutical, life sciences, and PBM clients on complex regulatory issues, including fraud and abuse, compliance, reimbursement and transactional matters.  

Subscribe to Stinson's
News & Insights
Jump to Page

We use cookies on our website to improve functionality and performance, analyze website traffic and enable social media features. By continuing to use our website, you agree to our use of cookies. For more information, please see our Cookie Policy.